CONFIRM, 0 NCT03063450
nivolumab alone (n=211) vs. placebo (n=111)
randomized controlled trial
nivolumab
nivolumab at a dose of 240 mg as a 30-min intravenous (IV) infusion, on day 1 ± 2 Q2W
placebo
placebo : sterile 0.9% sodium chloride as a 30-min IV infusion
There will be no dose escalations or reductions allowed.
malignant mesothelioma (mMS) - 2nd line (L2)
double-blind
approximately 25 UK centres
P3/
Results showed that the trial met both its coprimary end points of overall survival (OS) and progression-free survival (PFS)